Physician

Matias Emanuel Valsecchi, M.D.

According to 2025 Medicare claims, Matias Valsecchi, M.D. (NPI: 1235338328) practices hematology/oncology in the Huntington-Ashland, WV-KY-OH market, with the plurality of this provider's patient population coming from Cabell, WV. This provider's primary affiliated billing organization is ST. MARY'S HIMG, LLC (NPI: 1184233454; TIN: 85-2017234) and primary practice location at 25705-8859. Valsecchi is affiliated with the Collaborative ACO 30, LLC (ACO ID: A5483), participating under the MSSP model.

Valsecchi's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 459 traditional Medicare patients, billed 1,781 HCPCS/CPT codes, and received $118,924 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 1,875 prescription claims across 339 beneficiaries totaling $4,143,682 in drug costs, led by Lenalidomide (Lenalidomide). 2023 DME data shows 28 claims. Open Payments data shows 130 records totaling $2,501. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $733,404 to $118,924. In contrast, Part D prescription costs have moved from a lower plateau to a higher plateau, from $523,387 to $4,143,682. For DME billing, this smaller-volume category moved up and down with repeated peaks and valleys, starting at $2,227 and ending at $24,660.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	378	53,706	$733,404
2016	444	73,397	$827,114
2017	455	61,365	$914,000
2018	493	73,919	$1,134,471
2019	532	158,395	$2,439,649
2020	516	82,055	$1,575,106
2021	478	1,638	$114,323
2022	456	1,548	$104,311
2023	461	1,604	$112,372
2024	459	1,781	$118,924

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	138	1,107	$523,387
2016	142	1,078	$978,702
2017	154	1,066	$677,902
2018	176	1,215	$1,328,825
2019	198	1,418	$1,314,288
2020	217	1,509	$1,999,138
2021	227	1,576	$2,814,236
2022	259	1,544	$2,835,227
2023	284	1,634	$2,429,958
2024	339	1,875	$4,143,682

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	61	$14,085
2016	N/R	115	$11,837
2017	N/R	111	$2,887
2018	N/R	138	$4,850
2019	N/R	468	$18,983
2020	N/R	322	$10,451
2021	N/R	63	$1,102
2022	N/R	13	$1,073
2023	N/R	28	$5,715
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	127	131	$130
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	89	126	$108
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	212	615	$71
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	131	221	$63
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	197	307	$47

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	55	1,540	$811,558
Revlimid	Lenalidomide	41	1,078	$690,033
Verzenio	Abemaciclib	38	1,022	$382,795
Pomalyst	Pomalidomide	13	350	$284,352
Eliquis	Apixaban	237	14,516	$279,176

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	130	$2,501	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Matias Emanuel Valsecchi, M.D.?

Tedicare shows public-source Medicare data for Matias Emanuel Valsecchi, M.D. (NPI 1235338328), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Matias Emanuel Valsecchi, M.D. have ACO affiliation data?

Matias Emanuel Valsecchi, M.D. is shown with ACO affiliation data for Collaborative ACO 30, LLC (MSSP, ACO ID A5483).

What billing organization is linked to Matias Emanuel Valsecchi, M.D.?

Matias Emanuel Valsecchi, M.D. is linked to ST. MARY'S HIMG, LLC (billing NPI 1184233454) in the available physician profile data.

Does Matias Emanuel Valsecchi, M.D. have Open Payments data?

Matias Emanuel Valsecchi, M.D. has 130 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.